<DOC>
	<DOC>NCT00471276</DOC>
	<brief_summary>Patients with advanced breast cancer to receive sunitinib (Sutent) once daily until disease progression.</brief_summary>
	<brief_title>Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically or cytologically proven diagnosis of breast cancer Metastatic or locally recurrent disease that is, in the opinion of the investigator, not amenable to resection or radiation therapy Patients with at least one measurable lesion as per RECIST Inflammatory breast cancer Prior treatment with VEGF inhibitors (unless in adjuvant setting at least 12 months ago)</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
</DOC>